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Abstract
Background: Targeting bacterial virulence factors is now gaining interest as an alternative strategy to develop new types of
anti-infective agents. It has been shown that thymol, when used at low concentrations, can inhibit the TSST-1 secretion in
Staphylococcus aureus. However, there are no data on the effect of thymol on the production of other exotoxins (e.g., a-
hemolysin and enterotoxins) by S. aureus.
Methodology/Principal Findings: Secretion of a-hemolysin, SEA and SEB in both methicillin-sensitive and methicillin-
resistant S. aureus isolates cultured with graded subinhibitory concentrations of thymol was detected by immunoblot
analysis. Hemolysin and tumor necrosis factor (TNF) release assays were performed to elucidate the biological relevance of
changes in a-hemolysin, SEA and SEB secretion induced by thymol. In addition, the influence of thymol on the transcription
of hla, sea, and seb (the genes encoding a-hemolysin, SEA and SEB, respectively) was analyzed by quantitative RT-PCR.
Thymol inhibited transcription of hla, sea and seb in S. aureus, resulting in a reduction of a-hemolysin, SEA and SEB secretion
and, thus, a reduction in hemolytic and TNF-inducing activities.
Conclusions/Significance: Subinhibitory concentrations of thymol decreased the production of a-hemolysin, SEA and SEB
in both MSSA and MRSA in a dose-dependent manner. These data suggest that thymol may be useful for the treatment of S.
aureus infections when used in combination with b-lactams and glycopeptide antibiotics, which induce expression of a-
hemolysin and enterotoxins at subinhibitory concentrations. Furthermore, the structure of thymol may potentially be used
as a basic structure for development of drugs aimed against these bacterial virulence factors.
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Introduction
Staphylococcus aureus is a leading cause of both community- and
hospital-acquired infections associated with significant morbidity
and mortality. This pathogen causes a wide spectrum of clinical
illnesses, including skin and soft tissue lesions, and lethal infections
such as osteomyelitis, endocarditis, pneumonia and septicemia [1].
The continuous emergence of methicillin-resistant S. aureus,
glycopeptide-insensitive S. aureus (GISA) and vancomycin-resistant
S. aureus strains (VRSA) has made it difficult to treat S. aureus
infections [2]. Moreover, it is well known that S. aureus can secrete
a number of exotoxins (e.g., hemolysins, enterotoxins, coagulase,
TSST-1 and protein A), which contributes to the ability of this
pathogen to cause such a variety of diseases [3].
a-hemolysin and enterotoxins are major virulence factors
secreted by S. aureus strains. a-hemolysin is a 33-kDa pore-forming
protein that has cytolytic, hemolytic and dermonecrotic activities.
A wide range of human cells, including erythrocytes, monocytes,
lymphocytes, macrophages and epithelial cells, are affected by a-
hemolysin. Staphylococcal enterotoxins (SEs) are the virulence
factors responsible for staphylococcal gastroenteritis and are one
cause of food poisoning in humans. The enterotoxins also have the
immunomodulatory properties of superantigens, stimulating
release of T-cell-derived cytokines and T-cell activation [4]. To
date, a number of SEs have been identified, including SEA-E,
SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN and SEO [5].
Like most staphylococcal exoproteins, a-hemolysin and SEs are
not expressed constitutively, but are primarily secreted during the
post-exponential growth phase [3]. Furthermore, the expression of
virulence factors is generally modulated in response to alterations
in cell-population density through a process referred to as quorum
sensing [6].
Thymol, a p-cymene-derived compound primarily found in
thyme, oregano and tangerine peel, is widely used in medicine for
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bacterial, anti-leishmanial and hepatoprotective activities [7–10].
Furthermore, we previously reported that thymol has antifungal
activity against clinical isolates of fluconazole-sensitive and -
resistant Candida albicans, and investigated the effect of thymol on
global gene expression of the model fungus Saccharomyces cerevisiae
[11,12]. It has been demonstrated that thymol is active against S.
aureus and can suppress the TSST-1 secretion in S. aureus when
used at low concentrations that minimally affect bacterial growth
[13,14]. However, to our knowledge, the effects of thymol on
secretion of a-hemolysin and enterotoxins by S. aureus remain
uncharacterized.
The goal of this study was to investigate the effect of
subinhibitory concentrations of thymol on the expression of a-
hemolysin and two major enterotoxins (SEA and SEB) by
methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S.
aureus (MRSA).
Results
Growth of S. aureus with subinhibitory concentrations of
thymol
The minimum inhibitory concentrations (MICs) of thymol
against 29 S. aureus strains were determined and ranged from 64 to
256 mg/ml. The MIC values of thymol against S. aureus ATCC
29213 and MRSA strain 2985 were 128 mg/ml. These results
indicate that the thymol structure could be an important basic
structure for development of novel anti-S. aureus drugs. The growth
curves of S. aureus ATCC 29213 cultured with graded subinhib-
itory concentrations of thymol are shown in Fig. 1A; Thymol, at
levels from 1/166MIC to 1/26MIC had no significant effects on
the growth of S. aureus. However, during culture with 16MIC of
thymol, the growth rate was significantly decreased; after 30, 180
and 360 min of thymol treatment, OD600 values were 57.2%,
51.8% and 53.6% of the control culture, respectively. The growth
of MRSA strain 2985 was affected by these concentrations of
thymol in similar manner (Fig. 1B).
Influence of thymol on a-hemolysin, SEA and SEB
production by S. aureus
Western blot assays were performed to detect the levels of a-
hemolysin, SEA and SEB produced by S. aureus. As exoproteins are
principally secreted during post-exponential growth, S. aureus
ATCC 29213 and MRSA 2985 were cultured with graded
subinhibitory concentrations of thymol to an OD600 of 2.5. As
shown inFig. 2,treatmentwiththymolresulted ina dose-dependent
decrease in the secretion of a-hemolysin, SEA and SEB. Culture
with 1/166MIC of thymol resulted in a recognizable reduction in
secretion of a-hemolysin, SEA and SEB; during culture with 1/26
MIC, little or no immunoreactive proteins could be detected in
strains ATCC 29213 and MRSA 2985.
The apparent reduction in secretion of a-hemolysin, SEA and
SEB could result from an increase in protease secretion by S. aureus
cultured in thymol-containing medium; to address this possibility,
extracellular proteases were quantified using azocasein. There was
no significant effect on protease secretion by ATCC 29213 or
MRSA 2985 cultured with 1/2 6 MIC of thymol (data not
shown).
Thymol attenuates hemolytic and TNF-inducing activities
of S. aureus supernatants
It has been shown that secretion of a-hemolysin by S. aureus results in
hemolysis of rabbit erythrocytes, while enterotoxins act as superanti-
gens, stimulating T-cells to release proinflammatory cytokines (e.g.,
TNF-a). Therefore, hemolysin and tumor necrosis factor (TNF) release
assays were performed to elucidate the biological relevance of the
reduction in a-hemolysin, SEA and SEB secretion induced by thymol.
When cultured with 1/166MIC of thymol, hemolysis of ATCC
29213 and MRSA 2985 culture supernatants were 62.2% and 70.5%
compared to respective control culture, respectively. Notably, during
culture with 1/46MIC or 1/26MIC of thymol, no hemolysis was
observed (Table 1); this dose-dependent attenuation of hemolysis was
observed in both strains. However, treatment with thymol did not
directly cause hemolysis of rabbit erythrocytes at 1 6MIC or 2 6
MIC concentrations. Additionally, there was little influence on the
hemolytic activity of culture supernatants when pre-incubated with a
2 6 MIC of thymol (data not shown). Although a-hemolysin is a
major hemolysin, S. aureus contains other hemolytic toxins, such as b-
and c-hemolysin. Therefore, not all hemolytic activity is due to a-
hemolysin. From the results of hemolysin assays, it is reasonable to
infer that the production of other hemolytic toxins in S. aureus may
also be inhibited by subinhibitory concentrations of thymol.
Figure 1. Growth curve for S. aureus ATCC 29213 (A) and MRSA
strain 2985 (B). (e), untreated S. aureus;(N), S. aureus cultured with
8 mg/ml thymol; (*), S. aureus cultured with 16 mg/ml thymol; (6), S.
aureus cultured with 32 mg/ml thymol; (g), S. aureus cultured with
64 mg/ml thymol; (%), S. aureus cultured with 128 mg/ml thymol. Values
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itory concentrations of thymol elicited reduced amounts of TNF-a
produced by spleen cells (Fig. 3). However, thymol did not directly
reduce TNF release at 16MIC or 26MIC concentrations. Thymol
diminished the TNF-inducing activity of S. aureus supernatants in a
dose-dependent manner.
Thymol diminishes the transcription of hla, sea, seb and
agrA in S. aureus
Since thymol significantly decreased the production of a-
hemolysin, SEA and SEB by S. aureus, we hypothesized that
thymol could affect transcription of hla, sea and seb. Quantitative
RT-PCR was performed to assess relative expression levels of hla,
sea and seb. Since the these genes are positively regulated by the
Agr two-component system [15], the transcription of agrA was also
investigated. A dose-dependent reduction of hla, sea, seb and agrA
transcription was observed in the S. aureus strain ATCC 29213
upon treatment with thymol (Fig. 4). For example, when cultured
with 1/2 6 MIC concentration of thymol, the transcriptional
levels of hla, sea, seb and agrA were decreased by 10.2-, 8.6-, 5.2 and
7.2-fold, respectively.
Discussion
The dramatic increase in methicillin-resistant S. aureus,i n
addition to the emergence of vancomycin-resistant isolates, has
accelerated and broadened the interest in the development of new
therapeutics to aid in the prevention and treatment of life-
threatening infections caused by these strains [16]. Currently,
there is a focus on identifying natural compounds that may serve
as basic structures for the development of novel anti-S. aureus drugs
[17]. Thymol, the major phenolic component of oregano oil, is
known for its wide spectrum of antimicrobial activity and has been
the subject of several investigations [18]. In this study, we have
demonstrated that thymol is active against both MSSA and
MRSA; therefore, thymol may potentially be used as a lead
Figure 2. Western blot analysis of a-hemolysin, SEA and SEB
production. Both strain ATCC 29213 (A) and MRSA 2985 (B) were
cultured with graded subinhibitory concentrations of thymol to an
OD600 of 2.5. Supernatants were subjected to SDS-PAGE. After transfer
to polyvinylidene fluoride membranes, proteins were stained with the
indicated antibodies against a-hemolysin, SEA and SEB. Horseradish
peroxidase-conjugated goat anti-rabbit antiserum was used as second-
ary antibody, and the blots were developed using the ECL substrate (GE
Healthcare, UK).
doi:10.1371/journal.pone.0009736.g002
Table 1. Hemolytic activities of a-hemolysin produced by S. aureus cultured with graded subinhibitory concentrations of thymol.
Strains Hemolysis (%) of rabbit erythrocytes by culture supernatant
a
08 mg/ml 16 mg/ml 32 mg/ml 64 mg/ml
ATCC 29213 100% 62.2%64.9 14.1%63.5
** NO. NO.
MRSA 2985 100% 70.5%66.2 26.5%64.2
* NO. NO.
aThe drug-free culture supernatants served as 100% hemolysis.
NO. means no hemolytic activity was observed.
Values represent the mean and standard error of three independent experiments.
*, p,0.05 and
**, p,0.01 compared to the corresponding control.
doi:10.1371/journal.pone.0009736.t001
Figure 3. TNF release from splenocytes stimulated with
supernatants of S. aureus. Spleen cells were stimulated with
supernatants of S. aureus previously grown to an OD600 of 2.5 in the
absence or presence of graded subinhibitory concentrations of thymol
in RPMI-1640. After 16 h of stimulation, TNF release was measured by
ELISA. Values represent the mean 6 SD for three independent
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could be used to fight drug-resistant S. aureus strains.
An alternate strategy that is gaining great interest is treatment
that targets bacterial virulence factors (e.g., enterotoxins, hemo-
lysins and adhesins) [19,20]. The pathogenicity of S. aureus, similar
to that of other Gram-positive bacteria, to a great extent, depends
on the production of numerous extracellular virulence factors.
Consequently, the clinical performance of antibiotics is not only
determined by their bactericidal or bacteriostatic activity, but also
by their influence on virulence factor release [21]. Many
antibiotics affect the secretion of exotoxins by S. aureus, especially
at suboptimal concentrations. Inhibitors of protein synthesis, such
as linezolid and clindamycin, significantly inhibit the production of
virulence factors (including a-hemolysin, SEA, SEB and protein A)
in S. aureus at subinhibitory concentrations [22,23]. In contrast,
bactericidal antibiotics that affect the cell wall (for example, b-
lactams and glycopeptides), induce the expression of a-hemolysin,
enterotoxins and TSST-1 through a stimulatory effect on
exoprotein synthesis [24]. It has also been demonstrated that
some plant compounds (e.g., oleuropein and epicatechin gallate)
and essential oils (e.g., oils of bay, cinnamon and clove) can
influence production of exotoxins when used at subinhibitory
concentrations [17,25,26]. The antibiotic-induced regulation of
virulence factors may result in either aggravation or attenuation of
the infection. Therefore, the regulation of toxin secretion is
extremely significant for diseases caused by S. aureus, and the
ability of antibiotics to affect these properties may be an important
criterion in selecting an antibiotic for therapy [27].
Many studies have indicated that, in addition to drug
resistance, S. aureus has the ability for increased virulence, which
may lead to more severe and widespread disease. For instance, Li
and colleagues reported that community-associated MRSA
USA300 and its progenitor USA500 were clearly distinct from
other MRSA strains. These strains displayed high virulence in
animal infection models and had the capacity to evade innate
host defense mechanisms. The increased virulence in the
USA300/USA500 sublineage was attributed to differential
expression of core genome-encoded virulence determinants, such
as phenol-soluble modulins and a-toxin [28]. Holden et al.h a v e
also provided evidence for the rapid evolution of virulence by
comparing complete genomes of two clinical S. aureus strains [29].
Furthermore, it has been demonstrated that virulence factors can
transfer between S. aureus and Staphylococcus epidermidis, which may
result in the transformation of S. epidermidis from a commensal
organism into a more aggressive opportunistic pathogen [30].
Taken together, these findings highlight the significance and
urgency of developing antimicrobial agents which target
virulence factors.
Figure 4. Relative expression of hla (A), sea (B), seb (C) and agrA (D) in S. aureus. S. aureus ATCC 29213 was cultured with different
subinhibitory concentrations of thymol to the post-exponential growth phase (t=240 min). Transcript levels were monitored by quantitative RT-PCR
as described in the Materials and Methods. The drug-free culture was used as calibrator. Values represent the mean 6 SD for three independent
experiments. * represents p,0.05 and ** represents p,0.01.
doi:10.1371/journal.pone.0009736.g004
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expressional and phenotypic analyses that subinhibitory concen-
trations of thymol reduce a-hemolysin, SEA and SEB secretion in
both MSSA and MRSA in a dose-dependent manner. These
results indicate that thymol may be useful for the treatment of S.
aureus infections when used in combination with b-lactams and
glycopeptide antibiotics, which could induce expression of a-
hemolysin and enterotoxins at subinhibitory concentrations.
Additionally, the structure of thymol may be used as a basic
structure for development of drugs aimed at the bacteria virulence
factors.
In view of the increasing incidence of antibiotics resistance,
there is also a continuing need to find more and improved
antimicrobial agents in the food industry. The SEs preformed
within the food could cause serious food-borne diseases, including
staphylococcal gastroenteritis and food poisoning. Furthermore,
SEs are a family of major serological types of heat stable
enterotoxins [31]. Consequently, the ability of thymol to decrease
the production of SEA and SEB adds impetus to its potential as a
novel food preservative.
The expression of most virulence factors by S. aureus is regulated
by a network of interacting regulators, such as agr, sar and sae [32].
Previous reports indicated that subinhibitory concentrations of
antibiotics may interfere with translation of one or more
regulatory gene products in S. aureus, and therefore may affect
transcription of exoprotein-encoding genes. For example, subin-
hibitory concentrations of clindamycin differentially inhibited the
transcription of exoprotein genes in S. aureus and acted partly
through sar [22]; subinhibitory concentrations of b-lactams
induced hemolytic activity in S. aureus through the SaeRS two-
component system [33]. In this study, quantitative RT-PCR was
used to investigate the influence of thymol on the agr locus of S.
aureus. Our results showed that thymol significantly inhibited agrA
transcription. However, the mechanisms by which S. aureus
controls virulence gene expression are fairly intricate and involve
an interactive, hierarchical regulatory cascade among the products
of the sar, agr, and other components [34]. Therefore, we presume
that the reduction of virulence factor production observed in our
study may partially depend on thymol-induced inhibition of the
Agr two-component system.
In conclusion, considering the broad-spectrum antimicrobial
activities of thymol, as well as the findings reported in this study,
we propose that thymol could potentially be used in the
pharmaceutical and food industries.
Materials and Methods
Ethics Statement
All animal studies were conducted according to the experimen-
tal practices and standards approved by the Animal Welfare and
Research Ethics Committee at Jilin University. The study was also
approved by the Institutional Review Board of the First Hospital
of Jilin University, and all patients provided written informed
consent for the collection of samples and subsequent analysis.
Bacterial strains and reagents
MSSA strain ATCC 29213 was obtained from the American
Type Culture Collection (ATCC). 28 clinical S. aureus isolates (15
MSSA and 13 MRSA) were isolated at the First Hospital of Jilin
University from blood samples of infected patients; the clinical
MRSA strain 2985, which has the ability to secrete a-hemolysin,
SEA and SEB, was chosen for further experiments. Luria-Bertani
(LB) broth was purchased from BD Biosciences, Inc. (Sparks, MD).
Thymol was purchased from Sigma-Aldrich (St. Louis, MO), and
dilutions were prepared in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St. Louis, MO).
Determination of Antibiotic MIC
MICs of thymol for S. aureus were evaluated in triplicate by a
broth microdilution method as recommended by the Clinical and
Laboratory Standards Institute [35]. The MIC was defined as the
lowest concentration at which no visible growth was observed.
Growth curves
S. aureus strain ATCC 29213 was cultured in LB to an OD600 of
0.3, and 100-ml volumes werealiquoted into six 500-ml Erlenmeyer
flasks. Thymol (dissolved in DMSO) was added to five of the
cultures to obtainfinal concentrations of 1/166MIC(8 mg/ml),1/
86MIC (16 mg/ml), 1/46MIC (32 mg/ml), 1/26MIC (64 mg/
ml), or 1 6MIC (128 mg/ml). The final DMSO concentration for
all conditions was 1% (v/v). A control culture received 1% DMSO
only. Following addition of thymol (or DMSO), bacteria were
cultured at 37uC with aeration and cell growth was monitored
spectrophotometrically by measuring the OD600 at 30 min
intervals. Three-ml samples of each culture were collected
immediately after the addition of thymol (t0) and after 30, 60, 90,
120, 150, 180, 210, 240, 270, 300, 330 and 360 min.
Western blot assay
Bacteria were cultured in LB containing subinhibitory concen-
trations of thymol to post-exponential growth phase (OD600 of 2.5,
equivalent to 1610
9 CFUs/ml). Supernatants were collected by
centrifugation, and the whole cells were removed through a 0.2-
mm filter. A 25 ml volume of the supernatant was used for
determination of a-hemolysin, SEA and SEB. Western blot
analysis was performed under the conditions described by Towbin
[36]. Antibodies to a-hemolysin, SEA and SEB were purchased
from Sigma-Aldrich.
Hemolysin assay
Bacteria were cultured in LB with graded subinhibitory
concentrations of thymol to the post-exponential growth phase
(OD600 of 2.5, equivalent to 1610
9 CFUs/ml). a-hemolysin levels
in bacterial culture supernatants were determined based on the
method of Rowe and Welch [37]. Briefly, bacterial samples
(0.5 ml) were centrifuged (5,5006g, 4uC, 1 min), the supernatant
was removed and 0.1 ml of supernatant was brought up to 1 ml in
hemolysin buffer (0.145 M NaCl, 0.02 M CaCl2). After incubation
with 25 ml of defibrinated rabbit blood (Biotech, Ltd., Changchun,
China) for 30 min at 37uC, samples were centrifuged (5,5006g,
room temperature, 1 min) and the optical densities of the
supernatants were measured at 543 nm.
Tumor necrosis factor (TNF) release assay
The TNF release assay was performed as described by Bernardo
with some modification [23]. Overnight cultures of MSSA ATCC
29213 and MRSA 2985 inRPMI-1640 (Invitrogen, CA,USA) were
diluted 30-fold in 500 ml of prewarmed RPMI-1640. Following
incubation for 30 min at 37uC with aeration, cultures were divided
into 100-ml aliquots. Graded concentrations of thymol (1/16, 1/8,
1/4 and 1/26MIC) were added to bacterial suspensions; following
the addition of thymol, cultures were incubated for an additional
4 h.The finalDMSO concentrationforall conditions was 1%(v/v).
The control culture was treated with 1% DMSO only. S. aureus
supernatants without antibiotic treatment served as controls.
Proteins secreted into the supernatants were filtered through a
0.2-mm filter and immediately analyzed as described below.
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weighing 18 to 22 g) were obtained from the Experimental Animal
Center of Jilin University (Changchun, China). Spleen cell
suspensions were prepared in RPMI-1640, washed and resus-
pended in complete RPMI-1640 medium (RPMI-1640 media
supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 IU/ml penicillin, 100 IU/ml streptomycin, 15 mM HEPES
and 50 mM 2-mercaptoethanol). A total of 10
6 (150 ml) cells were
dispensed into wells of a 96-well tissue culture plate. 50 mlo fS.
aureus culture supernatants were added to the tissue culture plate.
After incubation for 16 h, supernatants were collected, centrifuged
(1,0006g for 5 min) and TNF in the supernatants was determined
by using the Mouse TNF-a ELISA MAX
TM Set Standard
(Biolegend, Inc., San Diego, USA), according to the instructions
of the manufacturer.
Quantitative RT-PCR
Strain ATCC 29213 was cultured in LB with graded
subinhibitory concentrations of thymol to the post-exponential
growth phase (t=240 min). RNA was prepared as described by
Sambanthamoorthy [38]. Briefly, cells were harvested by centri-
fugation (5,0006g for 5 min at 4uC) and resuspended in TES
buffer containing 100 mg/ml lysostaphin (Sigma-Aldrich). The
samples were incubated at 37uC for 10 min and then applied to a
Qiagen RNeasy Maxi column to isolate total bacterial RNA,
according to the manufacturer’s directions. The optional on-
column RNase-free DNase I (Qiagen, Hilden, Germany) treat-
ment was performed to remove contaminating DNA. After
isolation of RNA, traces of contaminating DNA were further
eliminated by treating RNA samples with RNase-free DNase I
(Ambion, Austin, TX) at 37uC for 20 min. Samples were either
used immediately or stored at 280uC. The quality, integrity, and
concentration of RNA were determined by using an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, Calif.) as described
by the manufacturer. The primer pairs used in quantitative RT-
PCR are listed in Table 2. RNA was reverse transcribed into
cDNA using the Takara RNA PCR kit (AMV) Ver. 3.0 (Takara,
Kyoto, Japan), according to the manufacturer’s instructions;
cDNA was stored at 220uC until needed. The PCR reactions
were performed in 25 ml total volume and contained SYBR
Premix Ex Taq
TM (Takara), as recommended by the manufac-
turer. The reactions were performed using the 7000 Sequence
Detection System (Applied Biosystems, Courtaboeuf, France).
Cycling conditions were as follows: one cycle at 95uC for 30 s; 40
cycles at 95uC for 5 s, 55uC for 30 s, and 72uC for 40 s; and one
dissociation step of 95uC for 15 s, 60uC for 30 s, and 95uC for
15 s. All samples were analysed in triplicate and normalized
against 16S rRNA expression. Relative expression levels were
determined by the (DDCt) method described in Applied Biosys-
tems User Bulletin no. 2 [39].
Statistical analysis
Experimental data were analyzed using the SPSS 12.0 statistical
software. Data were expressed as the mean 6 SD. Statistical
differences were examined using independent Student t-test. A p
value less than 0.05 was considered to be statistically significant.
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